Works by Warmuth, Markus

Results: 12

Allosteric inhibition of BCR-ABL.
Published in:
Cell Cycle, 2010, v. 9, n. 18, p. 3710, doi. 10.4161/cc.9.18.13232
By:
- Hassan, A. Quamrul;
- Sharma, Sreenath V.;
- Warmuth, Markus
Publication type:
Article
Hedgehog pathway activation in chronic myeloid leukemia.
Published in:
Cell Cycle, 2010, v. 9, n. 17, p. 3449, doi. 10.4161/cc.9.17.12945
By:
- Jagani, Zainab;
- Dorsch, Marion;
- Warmuth, Markus
Publication type:
Article
Interaction of the receptor tyrosine kinase p145c- kit with the p210 bcr/abl kinase in myeloid cells.
Published in:
British Journal of Haematology, 1996, v. 94, n. 1, p. 5, doi. 10.1046/j.1365-2141.1996.6102053.x
By:
- Hallek, Michael;
- Danhauser-Riedl, Susanne;
- Herbst, Ronald;
- Warmuth, Markus;
- Winkler, Almut;
- Kolb, Hans-Jochen;
- Druker, Brian;
- Griffin, James D.;
- Emmerich, Bertold;
- Ullrich, Axel
Publication type:
Article
Role of p21WAF1/CIP1 as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
Published in:
Annals of Hematology, 2008, v. 87, n. 3, p. 183, doi. 10.1007/s00277-007-0400-9
By:
- Forster, Karin;
- Obermeier, Axel;
- Mitina, Olga;
- Simon, Nicola;
- Warmuth, Markus;
- Krause, Günter;
- Hallek, Michael
Publication type:
Article
Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner.
Published in:
Annals of Hematology, 2007, v. 86, n. 11, p. 777, doi. 10.1007/s00277-007-0344-0
By:
- Mitina, Olga;
- Warmuth, Markus;
- Krause, Günter;
- Hallek, Michael;
- Obermeier, Axel
Publication type:
Article
Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators.
Published in:
Nature Communications, 2019, v. 10, n. 1, p. 1, doi. 10.1038/s41467-018-08150-5
By:
- Aird, Daniel;
- Teng, Teng;
- Huang, Chia-Ling;
- Pazolli, Ermira;
- Banka, Deepti;
- Cheung-Ong, Kahlin;
- Eifert, Cheryl;
- Furman, Craig;
- Wu, Zhenhua Jeremy;
- Seiler, Michael;
- Buonamici, Silvia;
- Fekkes, Peter;
- Karr, Craig;
- Palacino, James;
- Park, Eunice;
- Smith, Peter G.;
- Yu, Lihua;
- Mizui, Yoshiharu;
- Warmuth, Markus;
- Chicas, Agustin
Publication type:
Article
Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion.
Published in:
PLoS ONE, 2017, v. 12, n. 11, p. 1, doi. 10.1371/journal.pone.0176181
By:
- Albacker, Lee A.;
- Wu, Jeremy;
- Smith, Peter;
- Warmuth, Markus;
- Stephens, Philip J.;
- Zhu, Ping;
- Yu, Lihua;
- Chmielecki, Juliann
Publication type:
Article
Essential role of stromally induced hedgehog signaling in B-cell malignancies.
Published in:
Nature Medicine, 2007, v. 13, n. 8, p. 944, doi. 10.1038/nm1614
By:
- Dierks, Christine;
- Grbic, Jovana;
- Zirlik, Katja;
- Beigi, Ronak;
- Englund, Nathan P.;
- Gui-Rong Guo;
- Veelken, Hendrik;
- Engelhardt, Monika;
- Mertelsmann, Roland;
- Kelleher, Joseph F.;
- Schultz, Peter;
- Warmuth, Markus
Publication type:
Article
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Published in:
Nature Genetics, 2004, v. 36, n. 5, p. 453, doi. 10.1038/ng1343
By:
- Hu, Yiguo;
- Liu, Yuhua;
- Pelletier, Shawn;
- Buchdunger, Elisabeth;
- Warmuth, Markus;
- Fabbro, Doriano;
- Hallek, Michael;
- Van Etten, Richard A;
- Li, Shaoguang
Publication type:
Article
Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).
Published in:
Cancer Chemotherapy & Pharmacology, 2019, v. 83, n. 1, p. 151, doi. 10.1007/s00280-018-3716-3
By:
- Rioux, Nathalie;
- Smith, Sherri;
- Korpal, Manav;
- O'Shea, Morgan;
- Prajapati, Sudeep;
- Zheng, Guo Zhu;
- Warmuth, Markus;
- Smith, Peter G.
Publication type:
Article
Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers.
Published in:
2019
By:
- Rioux, Nathalie;
- Kim, Amy;
- Nix, Darrell;
- Bowser, Todd;
- Warmuth, Markus;
- Smith, Peter G.;
- Schindler, Joanne
Publication type:
journal article
Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).
Published in:
2018
By:
- Rioux, Nathalie;
- Smith, Sherri;
- Korpal, Manav;
- O'Shea, Morgan;
- Prajapati, Sudeep;
- Zheng, Guo Zhu;
- Warmuth, Markus;
- Smith, Peter G
Publication type:
journal article

Works by Warmuth, Markus

Allosteric inhibition of BCR-ABL.

Hedgehog pathway activation in chronic myeloid leukemia.

Interaction of the receptor tyrosine kinase p145<sup>c- kit</sup> with the p210<sup> bcr/abl</sup> kinase in myeloid cells.

Role of p21<sup>WAF1/CIP1</sup> as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.

Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner.

Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators.

Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion.

Essential role of stromally induced hedgehog signaling in B-cell malignancies.

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.

Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).

Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers.

Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).